Login to Your Account

Newly retooled Realm advancing lead drug as immunomodulator

By Nuala Moran
Staff Writer

Tuesday, January 31, 2017

LONDON – Following a total corporate makeover and a revamp of its technology, Realm Therapeutics plc has announced its rebirth with the filing of an FDA IND for a phase II study of its lead product, PRO22.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription